Lipids of the Human Tear Film and Their Effect on Tear Stability
| Status: | Completed |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 12/24/2017 |
| Start Date: | July 2008 |
| End Date: | December 2010 |
This prospective, randomized, comparative clinical trial evaluates the effect of either oral
doxycycline, oral essential fatty acid, or topical azithromycin to modify the secretions of
the meibomian gland in subjects with meibomian gland dysfunction and/or dry eye disease.
doxycycline, oral essential fatty acid, or topical azithromycin to modify the secretions of
the meibomian gland in subjects with meibomian gland dysfunction and/or dry eye disease.
Subjects with meibomian gland dysfunction undergo expression of the meibomian gland secretion
prior to beginning treatment with either oral doxycycline or topical azithromycin solution.
Doxycycline is dosed at 100 mg bid; topical azithromycin is delivered once per day as a 1%
solution. Treatment with doxycycline is for two months; treatment with topical azithromycin
is for one month. Following treatment, meibomian glands are again expressed and the lipids
measured by spectroscopy (FTIR, MALDI-TOF, NMR)for characterization of structure and
function. Analysis for presence of doxcycline or azithromycin is also performed. Changes in
lipid parameters are correlated with clinical signs and symptoms of disease.
prior to beginning treatment with either oral doxycycline or topical azithromycin solution.
Doxycycline is dosed at 100 mg bid; topical azithromycin is delivered once per day as a 1%
solution. Treatment with doxycycline is for two months; treatment with topical azithromycin
is for one month. Following treatment, meibomian glands are again expressed and the lipids
measured by spectroscopy (FTIR, MALDI-TOF, NMR)for characterization of structure and
function. Analysis for presence of doxcycline or azithromycin is also performed. Changes in
lipid parameters are correlated with clinical signs and symptoms of disease.
Inclusion Criteria:
- Meibomian gland dysfunction
Exclusion Criteria:
- Lid margin scarring; herpetic blepharitis
We found this trial at
1
site
Louisville, Kentucky 40202
Principal Investigator: Gary N Foulks, MD
Phone: 502-852-6150
Click here to add this to my saved trials
